Education
About Us
Working with TipRanks
Follow Us
Evaxion Biotech (EVAX)
NASDAQ:EVAX
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.58Last Year’s EPS
-0.6Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 27, 2025
|% Change Since: 47.34%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with strong R&D progress and a promising partnership with Merck, despite challenges posed by financial market uncertainties affecting deal execution.Company Guidance
During the Evaxion First Quarter 2025 Conference Call, CEO Christian Kanstrup highlighted key metrics and developments. The company is on track to achieve significant milestones, including a potential $10 million option exercise with Merck in the latter half of the year. Their business development target remains to secure at least two new deals by year-end. R&D progress was notable, with EVX-01 showing promising data; 80% of its new antigens elicited an immune response. Financially, Evaxion strengthened its position, ending Q1 with $17.8 million in cash, up from $6 million at the end of 2024, and forecasts a $14 million operational cash burn for the year, extending its runway to mid-2026. The net loss for Q1 was $1.6 million, while equity improved to $10.3 million. The company remains focused on its multi-partner strategy and aims to maintain its momentum in the coming months.Partnership with Merck on Track
The partnership with Merck is progressing towards a potential option exercise in the second half of the year, which could result in a $10 million milestone payment.
Strong R&D Progress
EVX-01 continues to yield positive data with 80% of new antigens eliciting an immune response. The first patient has been dosed in a one-year trial extension.
Improved Financial Position
Cash position improved to $17.8 million from $6 million, providing a runway until mid-2026, with operational cash burn estimated at $14 million for the year.
Active Scientific Engagement
Evaxion had a strong presence at several scientific conferences, crucial for engaging with potential partners and solidifying their multi-partner strategy.
EVAX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
EVAX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 27, 2025 | $1.88 | $2.36 | +25.53% |
Apr 01, 2025 | $1.85 | $1.66 | -10.27% |
Oct 31, 2024 | $13.80 | $13.35 | -3.26% |
Aug 14, 2024 | $13.52 | $13.76 | +1.78% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Evaxion Biotech (EVAX) report earnings?
Evaxion Biotech (EVAX) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Evaxion Biotech (EVAX) earnings time?
Evaxion Biotech (EVAX) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EVAX EPS forecast?
EVAX EPS forecast for the fiscal quarter 2025 (Q2) is -0.58.